NASDAQ:INBX Inhibrx (INBX) Stock Price, News & Analysis $12.30 -1.04 (-7.80%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Inhibrx Stock (NASDAQ:INBX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Inhibrx alerts:Sign Up Key Stats Today's Range$11.89▼$14.0050-Day Range$12.24▼$14.7252-Week Range$10.80▼$35.42Volume172,507 shsAverage Volume215,185 shsMarket Capitalization$178.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewInhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Read More… Remove Ads Inhibrx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreINBX MarketRank™: Inhibrx scored higher than 35% of companies evaluated by MarketBeat, and ranked 682nd out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Inhibrx.Read more about Inhibrx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Inhibrx are expected to decrease in the coming year, from $104.88 to ($12.08) per share.Read more about Inhibrx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.60% of the float of Inhibrx has been sold short.Short Interest Ratio / Days to CoverInhibrx has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Inhibrx has recently decreased by 19.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibrx does not currently pay a dividend.Dividend GrowthInhibrx does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-1.21 Percentage of Shares Shorted9.60% of the float of Inhibrx has been sold short.Short Interest Ratio / Days to CoverInhibrx has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Inhibrx has recently decreased by 19.71%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.21 News SentimentInhibrx has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Inhibrx this week, compared to 1 article on an average week.Search Interest1 people have searched for INBX on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inhibrx insiders have not sold or bought any company stock.Percentage Held by Insiders22.20% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inhibrx's insider trading history. Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter. Email Address INBX Stock News HeadlinesInhibrx Biosciences reshuffles leadership, appoints new CSO and PresidentApril 3, 2025 | investing.comInhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and PresidentApril 1, 2025 | prnewswire.comTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 7, 2025 | Porter & Company (Ad)Inhibrx Biosciences Full Year 2024 Earnings: Beats ExpectationsMarch 19, 2025 | finance.yahoo.comInhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 18, 2025 | finanznachrichten.deInhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 17, 2025 | prnewswire.comInhibrx's SWOT analysis: oncology biotech stock faces pivotal year aheadJanuary 22, 2025 | msn.comInhibrx Biosciences Inc (INBX) Gets a Hold from JMP SecuritiesJanuary 22, 2025 | markets.businessinsider.comSee More Headlines INBX Stock Analysis - Frequently Asked Questions How have INBX shares performed this year? Inhibrx's stock was trading at $15.40 at the beginning of the year. Since then, INBX stock has decreased by 20.0% and is now trading at $12.32. View the best growth stocks for 2025 here. How were Inhibrx's earnings last quarter? Inhibrx, Inc. (NASDAQ:INBX) announced its quarterly earnings data on Monday, March, 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.88) by $0.21. The firm earned $0.10 million during the quarter. When did Inhibrx IPO? Inhibrx (INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. How do I buy shares of Inhibrx? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibrx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Shopify (SHOP), Zoom Video Communications (ZM), CrowdStrike (CRWD) and Moderna (MRNA). Company Calendar Last Earnings3/17/2025Today4/07/2025Next Earnings (Estimated)6/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INBX CIK1739614 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees166Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,960,000.00 Net MarginsN/A Pretax Margin110,409.73% Return on Equity-113.74% Return on Assets-80.56% Debt Debt-to-Equity RatioN/A Current Ratio4.70 Quick Ratio4.70 Sales & Book Value Annual Sales$200,000.00 Price / Sales982.12 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares14,476,000Free Float11,262,000Market Cap$196.42 million OptionableOptionable BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:INBX) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThinking of buying Nvidia? Read this firstI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.